Tyrosine kinase inhibitor and pharmaceutical composition comprising same

1. A compound or an enantiomer, a diastereomer, a geometric isomer, a solvate or a pharmaceutically acceptable salt thereof represented by formula (II);

wherein, the structural formula of the formula (II) is as follows:

R 1 is C 1-6 alkoxy, C 1-6 heteroalkyl-O— or imidazolyl, each optionally substituted by a member selected from the group consisting of H, C 1-6 alkyl and aryl;

R 2 is selected from H, OH, NH 2 , halogen, CN, —C(═O)N(R 2d1 )(R 2d2 ), —NH(R 2d1 )C(═O)R 2d2 , —C(═O)OR 2d3 and C 1-7 alkyl; wherein the C 1-7 alkyl is optionally substituted by a member selected from the group consisting of halogen and OH, wherein, R 2d1 , R 2d2 and R 2d3 are each independently selected from H, OH, NH 2 , CN, C 1-7 alkyl, C 1-7 heteroalkyl, 3-6 membered cycloalkyl and 3-6 membered heterocycloalkyl, or R 2d1 and R 2d2 together form a 4-7 membered ring, wherein the C 1-7 alkyl, C 1-7 heteroalkyl, 3-6 membered cycloalkyl and 3-6 membered heterocycloalkyl are each optionally substituted by a member selected from the group consisting of halogen, OH, Me and Et;

R 10 is selected from H, OH, NH 2 , CN and halogen;

A is phenyl, which is optionally substituted by a member selected from the group consisting of H, F, Cl, Br, I, OH, CN, NH 2 ,

 Me and Et,

R 11 is

wherein, Y is S;

R 7 , R 8 and R 9 are each independently selected from H; and C 1-7 alkyl, C 1-7 heteroalkyl, 3-6 membered cycloalkyl, 3-6 membered heterocycloalkyl, 5-6 membered aryl, 5-6 membered heteroaryl, 3-6 membered cycloalkyl-C 1-3 alkyl-, 3-6 membered heterocycloalkyl-C 1-3 alkyl-, 5-6 membered aryl-C 1-3 alkyl-, C 2-7 alkynyl and

 each optionally substituted by a member selected from the group consisting of halogen, CF 3 , CN, D, OH,

 and C 1-3 alkyl; or

the structural unit

 is selected from

 each optionally substituted by a member selected from the group consisting of halogen, CF 3 , CN, D, OH,

 and C 1-3 alkyl; or

the structural unit

 is selected from

2. A compound or an enantiomer, a diastereomer, a geometric isomer, a solvate or a pharmaceutically acceptable salt thereof according to claim 1 , wherein R 7 , R 8 and R 9 are each independently selected from H; and C 1-4 alkyl, C 1-2 alkyl-S—C 1-3 alkyl-, C 1-2 alkyl-N—C 1-3 alkyl-, C 1-2 alkyl-O—C 1-3 alkyl-, 3-6 membered cycloalkyl, 3-6 membered cycloalkyl-C 1-2 alkyl, pyrrolidone, 5-6 membered lactone, pyrrolidinyl, piperidinyl, tetrahydropyranyl, morpholinyl, thiazolyl, pyrazolyl, phenyl, pyridyl, morpholinyl-C 1-2 alkyl-, phenyl-C 1-2 alkyl-, pyridyl-C 1-2 alkyl-, C 0-2 alkyl-alkynyl-C 1-2 alkyl- and

each optionally substituted by a member selected from the group consisting of halogen, CF 3 , CN, D, OH,

and C 1-30 alkyl.

3. A compound or an enantiomer, a diastereomer, a geometric isomer, a solvate or a pharmaceutically acceptable salt thereof according to claim 2 , wherein

R 7 , R 8 and R 9 are each independently selected from H; and Me,

 each optionally substituted by a member selected from the group consisting of halogen, CF 3 , CN, D, OH,

 and C 1-3 alkyl; or

the structural unit

 is selected from

 each optionally substituted by a member selected from the group consisting of halogen, CF 3 , CN, D, OH,

 and C 1-3 alkyl.

4. A compound or an enantiomer, a diastereomer, a geometric isomer, a solvate or a pharmaceutically acceptable salt thereof according to claim 3 , wherein R 7 , R 8 and R 9 are each independently selected from H, Me,

or the structural unit

is selected from

or the structural unit

is selected from

5. A compound or an enantiomer, a diastereomer, a geometric isomer, a solvate or a pharmaceutically acceptable salt thereof according to claim 1 , wherein R 1 is selected from C 1-6 alkoxy, O(CH 2 ) n R 1d1 and

wherein n is an integer of 1 to 6, R 1d1 is C 1-6 alkoxy or NR 1d5 R 1d6 , wherein, R 1d5 and R 1d6 are each independently H or C 1-6 alkyl, R 1d2 , R 1d3 and R 1d4 are each independently H, C 1-6 alkyl or aryl;

R 2 is selected from H, CN, halo C 1-3 alkyl, hydroxy C 1-3 alkyl, —C(═O)N(R 2d1 )(R 2d2 ), —NH(R 2d1 )C(═O)R 2d2 and —C(═O)OR 2d3 .

6. A compound or an enantiomer, a diastereomer, a geometric isomer, a solvate or a pharmaceutically acceptable salt thereof according to claim 1 , wherein A is

which is optionally substituted by a member selected from the group consisting of H, F, Cl, Br, I, OH, CN, NH 2 ,

Me and Et.

7. A compound or an enantiomer, a diastereomer, a geometric isomer, a solvate or a pharmaceutically acceptable salt thereof according to claim 1 , wherein R 11 is

8. A compound or an enantiomer, a diastereomer, a geometric isomer, a solvate or a pharmaceutically acceptable salt thereof according to claim 1 , wherein R 1 is

R 2 is selected from H, CN, CF 3 ,

9. A compound or an enantiomer, a diastereomer, a geometric isomer, a solvate or a pharmaceutically acceptable salt thereof according to claim 1 , wherein R 2d1 , R 2d2 and R 2d3 are each independently selected from H, OH, methyl,

or the structural unit —N(R 2d1 R 2d2 —) is selected from the group consisting of

10. A compound or an enantiomer, a diastereomer, a geometric isomer, a solvate or a pharmaceutically acceptable salt thereof according to claim 1 , wherein the structure is shown as formula (III)

11. A compound or an enantiomer, a diastereomer, a geometric isomer, a solvate or a pharmaceutically acceptable salt thereof according to claim 1 , wherein the structure is shown as formula (V)

wherein, in the formula (V), Y is S;

T is C(R 6 );

R 3 , R 4 , R 5 , R 6 are each independently selected from H, OH, NH 2 , CN, halogen, Me and Et;

R 7 , R 8 , R 9 are each independently selected from H; and C 1-7 alkyl, C 1-7 heteroalkyl, 3-6 membered cycloalkyl, 3-6 membered heterocycloalkyl, 5-6 membered aryl, 5-6 membered heteroaryl, 3-6 membered cycloalkyl-C 1-3 alkyl-, 3-6 membered heterocycloalkyl-C 1-3 alkyl-, 3-6 membered heterocycloalkyl-C 1-3 alkyl-, 5-6 membered aryl-C 1-3 alkyl-, C 2-7 alkynyl and

 each optionally substituted by a member selected from the group consisting of halogen, CF 3 , CN, D, OH,

 and C 1-3 alkyl.

12. A compound or an enantiomer, a diastereomer, a geometric isomer, a solvate or a pharmaceutically acceptable salt thereof according to claim 11 , wherein R 3 , R 4 , R 5 , R 6 are each independently selected from H, F, Cl, Br, I, OH, CN, NH 2 .

13. A compound or an enantiomer, a diastereomer, a geometric isomer, a solvate or a pharmaceutically acceptable salt thereof according to claim 11 , wherein R 7 , R 8 and R 9 are each independently selected from H; and Me,

each optionally substituted by a member selected from the group consisting of halogen, CF 3 , CN, D, OH

and C 1-3 alkyl.

14. A compound or an enantiomer, a diastereomer, a geometric isomer, a solvate or a pharmaceutically acceptable salt thereof according to claim 1 , wherein the structure is shown as formula (IX)

wherein, Y is S;

T is C(R 6 );

R 3 , R 4 , R 5 , R 6 are each independently selected from H, OH, NH 2 , CN, halogen, and Me and Et;

R 8 , R 9 are each independently selected from H; and C 1-7 alkyl, C 1-7 heteroalkyl, 3-6 membered cycloalkyl, 3-6 membered heterocycloalkyl, 5-6 membered aryl, 5-6 membered heteroaryl, 3-6 membered cycloalkyl-C 1-3 alkyl-, 3-6 membered heterocycloalkyl-C 1-3 alkyl-, 5-6 membered aryl-C 1-3 alkyl-, C 2-7 alkynyl,

 each optionally substituted by a member selected from the group consisting of halogen, CF 3 , CN, D, OH,

and C 1-3 alkyl.

15. A compound or an enantiomer, a diastereomer, a geometric isomer, a solvate or a pharmaceutically acceptable salt thereof according to claim 14 , wherein R 3 , R 4 , R 5 , R 6 are each independently selected from H, F, Cl, Br, I, OH, CN, NH 2 .

16. A compound or an enantiomer, a diastereomer, a geometric isomer, a solvate or a pharmaceutically acceptable salt thereof according to claim 14 , wherein R 8 and R 9 are each independently selected from H, Me,

or the structural unit

is selected from

or the structural unit

is selected from

17. A compound or an enantiomer, a diastereomer, a geometric isomer, a solvate or a pharmaceutically acceptable salt thereof, wherein the structure of the compound is selected from:

18. A pharmaceutical composition comprising the compound or enantiomer, diastereoisomer, geometric isomer, solvate or pharmaceutically acceptable salt thereof according to claim 1 and at least one pharmaceutically acceptable carrier, the pharmaceutical composition is tablet, suppository, dispersible tablet, enteric tablet, chewable tablet, orally disintegrating tablet, capsule, sugar coated tablet, granule, dry powder, oral solution, small volume injection, or freeze-dried powder injection, the pharmaceutically acceptable carrier includes one or more substances selected from diluents, solubilizers, disintegrants, suspending agents, lubricants, binders, fillers, flavoring agents, sweetening agents, antioxidants, surfactants, preservatives, encapsulants and pigments.

19. A method for treating tumors comprising administering to a patient in need thereof a therapeutically effective amount of the compound or enantiomer, diastereoisomer, geometric isomer, solvate or pharmaceutically acceptable salt thereof according to claim 1 , wherein the tumors comprises solid tumors and blood-borne tumors; the solid tumors comprises rhabdomyosarcoma, retinoblastoma, ewing sarcoma, neuroblastoma and osteosarcoma; the blood-borne tumors comprises, but are not limited to leukemia, lymphoma, multiple myeloma, and various acute or chronic myeloid neoplasms.

20. A compound or an enantiomer, a diastereomer, a geometric isomer, a solvate or a pharmaceutically acceptable salt thereof according to claim 1 , wherein A is selected from

21. A compound or an enantiomer, a diastereomer, a geometric isomer, a solvate or a pharmaceutically acceptable salt thereof according to claim 11 , wherein R 7 , R 8 and R 9 are each independently selected from H, Me,